Amgen sells $4.0 billion of senior notes maturing 2031 to 2056
Amgen issued and sold $4.0 billion of senior unsecured notes in four tranches on February 17, 2026, under an effective Form S-3 shelf registration. Net proceeds were approximately $3.96 billion after underwriters' discounts and offering expenses, and the notes carry fixed rates from 4.200% to 5.650%. The filing describes new debt obligations rather than a change in operations or earnings.
Key points
- Four tranches: $1.0 billion of 4.200% notes due 2031, $1.75 billion of 4.850% notes due 2036, $500 million of 5.500% notes due 2046, and $750 million of 5.650% notes due 2056
- Net proceeds to the company of approximately $3,961,495,000
- Interest is paid semi-annually on February 19 and August 19, starting August 19, 2026
- Holders may require repurchase at 101% of principal plus accrued interest upon a change in control triggering event
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 19, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.